PRESS RELEASE published on 05/07/2026 at 10:11, 6 months ago Virbac : Declaration of the number of shares and voting rights 04/2026 Declaration of the number of shares and voting rights for VIRBAC on Euronext Paris. Total voting rights: 12,707,056. Total shares: 8,390,660 as of April 30, 2026 Euronext Paris Voting Rights Shares Financial Market VIRBAC
BRIEF published on 04/07/2026 at 11:10, 7 months ago Virbac: Declaration on voting rights as of March 31, 2026 Voting Rights Euronext Actions Finance VIRBAC
PRESS RELEASE published on 03/17/2026 at 19:00, 7 months 21 days ago Virbac: Public Release of the Year-End Consolidated Accounts at 31 December 2025
BRIEF published on 12/16/2025 at 09:58, 10 months 22 days ago Virbac acquires Thyronorm for the treatment of feline hyperthyroidism Acquisition Animal Health Feline Hyperthyroidism VIRBAC Thyronorm
BRIEF published on 12/16/2025 at 09:58, 10 months 22 days ago Virbac Acquires Thyronorm to Combat Feline Hyperthyroidism Veterinary Medicine Animal Health Feline Hyperthyroidism VIRBAC Thyronorm
PRESS RELEASE published on 12/16/2025 at 09:53, 10 months 22 days ago VIRBAC: Feline Hyperthyroidism: Virbac acquires Thyronorm Virbac acquires innovative drug Thyronorm from Norbrook to stabilize feline hyperthyroidism, expanding distribution in key markets and enhancing senior cats' quality of life Acquisition Feline Hyperthyroidism VIRBAC Thyronorm Senior Cats
BRIEF published on 11/07/2025 at 15:44, 1 year ago Virbac: Update on shares and voting rights Euronext Paris Voting Rights Actions Transparency VIRBAC
BRIEF published on 09/12/2025 at 17:50, 1 year 1 month ago Virbac Reports Solid Growth in 2025 First Half Results Revenue Growth Operating Income VIRBAC 2025 Forecast Global Market Performance
PRESS RELEASE published on 09/12/2025 at 17:45, 1 year 1 month ago Virbac: 2025 Half-year results Virbac reports solid revenue growth of 5.6% in the first half of 2025, meeting adjusted operating income expectations. Targets for 2025 confirmed with revenue growth of 4-6% expected Financial Results Revenue Growth Operating Income VIRBAC Targets Confirmed
BRIEF published on 08/18/2025 at 09:35, 1 year 2 months ago Virbac reveals the remuneration of its new CEO General Manager Remuneration VIRBAC Free Shares Paul Martingell
Published on 11/06/2026 at 22:15, 1 day 4 hours ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 1 day 13 hours ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 1 day 13 hours ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 1 day 13 hours ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/07/2026 at 13:35, 12 hours 45 minutes ago Eurobattery Minerals board member and CEO remanded in custody in Sweden
Published on 11/06/2026 at 20:15, 1 day 6 hours ago African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing
Published on 11/06/2026 at 19:15, 1 day 7 hours ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA suspends the interest payment on the bond 2024/2029 due on 8 November 2026.
Published on 11/06/2026 at 19:00, 1 day 7 hours ago Finexity AG: FINEXITY issues 2026/2030 bond with a minimum of 7.00% p.a. – either conventionally in a securities account or as a crypto security in a wallet
Published on 11/06/2026 at 18:32, 1 day 7 hours ago EQS-Adhoc: Finexity AG: FINEXITY issues 2026/2030 bond
Published on 11/06/2026 at 17:54, 1 day 8 hours ago Disclosure of Share Capital and Voting Rights as of October 31, 2026
Published on 11/06/2026 at 17:35, 1 day 8 hours ago Disclosure of the number of shares and the total number of voting rights as of October 31, 2026
